共 325 条
[1]
Kovacs G(1997)The Heidelberg classification of renal cell tumours J Pathol 183 131-133
[2]
Akhtar M(2009)Renal cell carcinoma Lancet 373 1119-1132
[3]
Beckwith BJ(2003)Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 843-852
[4]
Bugert P(1995)Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 688-696
[5]
Cooper CS(2005)Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 133-141
[6]
Delahunt B(2009)Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590
[7]
Eble JN(2013)External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study Lancet Oncol 14 141-148
[8]
Fleming S(2017)FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis The Oncologist 22 311-317
[9]
Ljungberg B(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290
[10]
Medeiros LJ(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454